Nadunolimab has been tested in clinical studies in more than 300 patients with various forms of cancer
Clinical studies focus on different types of combination therapies
Fast Track Designation (2025) and Orphan Drug Designation (2021) for the Treatment of Pancreatic Cancer
CANxx
Preclinical project with the goal of developing an IL1RAP-based bispecific antibody with an undisclosed second target
CAN14 is Cantargia's newest project created from the CANxx platform
CANxx
IL1RAP-based platform (knowledge, technology and antibody platform)
Enables Cantargia to develop novel IL1RAP-binding antibodies with unique mechanisms of action
Strategic partnerships
CAN10
IL1RAP antibody developed for the treatment of autoimmune and inflammatory diseases
Currently in clinical development with ongoing phase 1 study
CAN10 was acquired by Otsuka Pharmaceutical in the summer of 2025, with significant future values for Cantargia (totaling up to $613 million in potential milestone payments plus up to double-digit royalties on sales)
